Trending Stories

Insights and updates

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

[ad_1] 225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical development Satoreotide expressed a superior pharmacokinetic profile relative […]